Literature DB >> 25404360

T-bet is critical for the development of acute graft-versus-host disease through controlling T cell differentiation and function.

Jianing Fu1, Dapeng Wang2, Yu Yu2, Jessica Heinrichs3, Yongxia Wu4, Steven Schutt4, Kane Kaosaard2, Chen Liu5, Kelley Haarberg2, David Bastian4, Daniel G McDonald6, Claudio Anasetti2, Xue-Zhong Yu7.   

Abstract

T-bet is a master regulator for IFN-γ production and Th1 differentiation. We evaluated the roles of T-bet and IFN-γ in T cell responses in acute graft-versus-host disease (GVHD) and found that T-bet(-/-) T cells induced significantly less GVHD compared with wild-type or IFN-γ(-/-) counterparts in both MHC-mismatched and MHC-matched but minor histocompatibility Ag-mismatched models driven by CD4 T cells. T-bet(-/-), but not IFN-γ(-/-), CD4 T cells had a markedly reduced ability to cause tissue damage in liver and gut. This distinct outcome is reflected by the differential gene expression on donor CD4 T cells deficient for T-bet or IFN-γ. At mRNA and protein levels, we defined several T-bet-dependent molecules that may account for the impaired ability of T-bet(-/-) T cells to migrate into target organs and to produce Th1-related cytokines. Moreover, these molecules were independent of either endogenous IFN-γ, such as CXCR3 and programmed death-1, or systematic IFN-γ, such as NKG2D, I-A(b), and granzyme B. Although both T-bet(-/-) and IFN-γ(-/-) CD4 T cells are prone to differentiate into Th17 cells, polarized Th17 cells deficient for T-bet but not for IFN-γ had a significantly reduced ability to cause GVHD. Finally, T-bet(-/-) T cells had a compromised graft-versus-leukemia effect, which could be essentially reversed by neutralization of IL-17 in the recipients. We conclude that T-bet is required for Th1 differentiation and migration, as well as for optimal function of Th17 cells. Thus, targeting T-bet or regulating its downstream effectors independent of IFN-γ may be a promising strategy to control GVHD in the clinic.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25404360      PMCID: PMC4314960          DOI: 10.4049/jimmunol.1401618

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  63 in total

Review 1.  Molecules and mechanisms of the graft-versus-leukaemia effect.

Authors:  Marie Bleakley; Stanley R Riddell
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

2.  Protective role of T-bet and Th1 cytokines in pulmonary graft-versus-host disease and peribronchiolar fibrosis.

Authors:  Kymberly M Gowdy; Julia L Nugent; Tereza Martinu; Erin Potts; Laurie D Snyder; W Michael Foster; Scott M Palmer
Journal:  Am J Respir Cell Mol Biol       Date:  2011-09-29       Impact factor: 6.914

3.  Opposing roles of interferon-gamma on CD4+ T cell-mediated graft-versus-host disease: effects of conditioning.

Authors:  L A Welniak; B R Blazar; M R Anver; R H Wiltrout; W J Murphy
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

4.  A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity.

Authors:  Yusuke Shono; Andrea Z Tuckett; Samedy Ouk; Hsiou-Chi Liou; Grégoire Altan-Bonnet; Jennifer J Tsai; Jennifer E Oyler; Odette M Smith; Mallory L West; Natalie V Singer; Ekaterina Doubrovina; Dmitry Pankov; Chandresh V Undhad; George F Murphy; Cecilia Lezcano; Chen Liu; Richard J O'Reilly; Marcel R M van den Brink; Johannes L Zakrzewski
Journal:  Cancer Discov       Date:  2014-02-18       Impact factor: 39.397

5.  In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations.

Authors:  Michael J Carlson; Michelle L West; James M Coghill; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

6.  The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses.

Authors:  Jinfang Zhu; Dragana Jankovic; Andrew J Oler; Gang Wei; Suveena Sharma; Gangqing Hu; Liying Guo; Ryoji Yagi; Hidehiro Yamane; George Punkosdy; Lionel Feigenbaum; Keji Zhao; William E Paul
Journal:  Immunity       Date:  2012-10-04       Impact factor: 31.745

7.  Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.

Authors:  Enrica Orsini; Roberto Bellucci; Edwin P Alyea; Robert Schlossman; Christine Canning; Stephen McLaughlin; Paolo Ghia; Kenneth C Anderson; Jerome Ritz
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

8.  Control of effector CD8+ T cell function by the transcription factor Eomesodermin.

Authors:  Erika L Pearce; Alan C Mullen; Gislâine A Martins; Connie M Krawczyk; Anne S Hutchins; Valerie P Zediak; Monica Banica; Catherine B DiCioccio; Darrick A Gross; Chai-An Mao; Hao Shen; Nezih Cereb; Soo Y Yang; Tullia Lindsten; Janet Rossant; Christopher A Hunter; Steven L Reiner
Journal:  Science       Date:  2003-11-07       Impact factor: 47.728

9.  Interferon-gamma prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice.

Authors:  H P Brok; P J Heidt; P H van der Meide; C Zurcher; J M Vossen
Journal:  J Immunol       Date:  1993-12-01       Impact factor: 5.422

10.  Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis.

Authors:  Estelle Bettelli; Brandon Sullivan; Susanne J Szabo; Raymond A Sobel; Laurie H Glimcher; Vijay K Kuchroo
Journal:  J Exp Med       Date:  2004-07-05       Impact factor: 14.307

View more
  19 in total

1.  Intracellular Delivery of Anti-pPKCθ (Thr538) via Protein Transduction Domain Mimics for Immunomodulation.

Authors:  E Ilker Ozay; Gabriela Gonzalez-Perez; Joe A Torres; Jyothi Vijayaraghavan; Rebecca Lawlor; Heather L Sherman; Daniel T Garrigan; Amy S Burnside; Barbara A Osborne; Gregory N Tew; Lisa M Minter
Journal:  Mol Ther       Date:  2016-09-16       Impact factor: 11.454

2.  T-bet Promotes Acute Graft-versus-Host Disease by Regulating Recipient Hematopoietic Cells in Mice.

Authors:  Jianing Fu; Yongxia Wu; Hung Nguyen; Jessica Heinrichs; Steven Schutt; Yuejun Liu; Chen Liu; Junfei Jin; Claudio Anasetti; Xue-Zhong Yu
Journal:  J Immunol       Date:  2016-02-22       Impact factor: 5.422

3.  T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model.

Authors:  David M Woods; Karrune V Woan; Fengdong Cheng; Andressa L Sodré; Dapeng Wang; Yongxia Wu; Zi Wang; Jie Chen; John Powers; Javier Pinilla-Ibarz; Yu Yu; Ya Zhang; Xuefeng Wu; Xiaoyan Zheng; Jeffrey Weber; Wayne W Hancock; Edward Seto; Alejandro Villagra; Xue-Zhong Yu; Eduardo M Sotomayor
Journal:  Blood       Date:  2017-05-26       Impact factor: 22.113

4.  Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning.

Authors:  Shannon R McCurdy; Vedran Radojcic; Hua-Ling Tsai; Ante Vulic; Elizabeth Thompson; Sanja Ivcevic; Christopher G Kanakry; Jonathan D Powell; Brian Lohman; Djamilatou Adom; Sophie Paczesny; Kenneth R Cooke; Richard J Jones; Ravi Varadhan; Heather J Symons; Leo Luznik
Journal:  Blood       Date:  2022-01-27       Impact factor: 22.113

5.  Immune Suppression in Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Thomas F Michniacki; Sung Won Choi; Daniel C Peltier
Journal:  Handb Exp Pharmacol       Date:  2022

6.  Newly found arsons ignite the fire of gut GVHD.

Authors:  Defu Zeng
Journal:  J Clin Invest       Date:  2018-01-29       Impact factor: 14.808

7.  PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease.

Authors:  Katiri J Snyder; Nina C Zitzer; Yandi Gao; Hannah K Choe; Natalie E Sell; Lotus Neidemire-Colley; Anora Ignaci; Charuta Kale; Raymond D Devine; Maria G Abad; Maciej Pietrzak; Min Wang; Hong Lin; Yang W Zhang; Gregory K Behbehani; Jane E Jackman; Ramiro Garzon; Kris Vaddi; Robert A Baiocchi; Parvathi Ranganathan
Journal:  JCI Insight       Date:  2020-04-23

Review 8.  Immunological basis for treatment of graft versus host disease after liver transplant.

Authors:  Vikrant Rai; Nicholas Edward Dietz; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2016-02-24       Impact factor: 4.473

9.  Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes.

Authors:  Rebecca S Hesterberg; Matthew S Beatty; Ying Han; Mario R Fernandez; Afua A Akuffo; William E Goodheart; Chunying Yang; Shiun Chang; Christelle M Colin; Aileen Y Alontaga; Jessica M McDaniel; Adam W Mailloux; Julia M R Billington; Lanzhu Yue; Shonagh Russell; Robert J Gillies; Sang Y Yun; Muhammad Ayaz; Nicholas J Lawrence; Harshani R Lawrence; Xue-Zhong Yu; Jianing Fu; Lancia N Darville; John M Koomen; Xiubao Ren; Jane Messina; Kun Jiang; Timothy J Garrett; Anjali M Rajadhyaksha; John L Cleveland; Pearlie K Epling-Burnette
Journal:  Blood       Date:  2020-08-13       Impact factor: 25.476

10.  LYG1 Deficiency Attenuates the Severity of Acute Graft-Versus-Host Disease via Skewing Allogeneic T Cells Polarization Towards Treg Cells.

Authors:  Huihui Liu; Zhengyu Yu; Bo Tang; Shengchao Miao; Chenchen Qin; Yuan Li; Zeyin Liang; Yongjin Shi; Yang Zhang; Qingya Wang; Miao Yan; Zhengyang Song; Hanyun Ren; Yujun Dong
Journal:  Front Immunol       Date:  2021-06-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.